Relay Therapeutics Inc [RLAY] stock is trading at $6.75, down -0.74%. An important factor to consider is whether the stock is rising or falling in short-term value. The RLAY shares have gain 6.47% over the last week, with a monthly amount drifted -11.18%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Relay Therapeutics Inc [NASDAQ: RLAY] stock has seen the most recent analyst activity on September 10, 2024, when Jefferies upgraded its rating to a Buy and also boosted its price target to $16 from $10.60. On September 10, 2024, downgrade downgraded it’s rating to Perform. Barclays upgraded its rating to a Overweight but stick to its price target of $15 on May 10, 2024. Jefferies upgraded its rating to a Hold but $12.50 remained the price target by the analyst firm on April 20, 2023. Raymond James upgraded its rating to Strong Buy for this stock on April 19, 2023, but kept the price target unchanged to $29. In a note dated April 13, 2023, Raymond James initiated an Outperform rating and provided a target price of $29 on this stock.
Relay Therapeutics Inc [RLAY] stock has fluctuated between $5.70 and $12.14 over the past year. Currently, Wall Street analysts expect the stock to reach $19.4 within the next 12 months. Relay Therapeutics Inc [NASDAQ: RLAY] shares were valued at $6.75 at the most recent close of the market. An investor can expect a potential return of 187.41% based on the average RLAY price forecast.
Analyzing the RLAY fundamentals
Relay Therapeutics Inc [NASDAQ:RLAY] reported sales of 35.21M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at -10.51%, Pretax Profit Margin comes in at -9.17%, and Net Profit Margin reading is -9.17%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -0.44 and Total Capital is -0.51. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.63 points at the first support level, and at 6.51 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.97, and for the 2nd resistance point, it is at 7.19.
Ratios To Look Out For
For context, Relay Therapeutics Inc’s Current Ratio is 15.64. On the other hand, the Quick Ratio is 15.64, and the Cash Ratio is 2.98. Considering the valuation of this stock, the price to sales ratio is 31.14, the price to book ratio is 1.32.
Transactions by insiders
Recent insider trading involved Rahmer Peter, that happened on Sep 27 ’24 when 245.0 shares were sold. Chief Financial Officer, Catinazzo Thomas completed a deal on Sep 27 ’24 to sell 6457.0 shares. Meanwhile, President, R&D Bergstrom Donald A sold 648.0 shares on Sep 27 ’24.
